Cognetivity Neurosciences Ltd.

Recent News

  • Cognetivity Neurosciences Announces Commercial Pilot with Large US Healthcare Provider

    Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, today announces that it has signed an agreement to conduct a broad-scale paid pilot project (the "Paid Project") with a large national US provider of healthcare services (the "Client").The Paid Project will run for a period of 12 months. It...

    2022-09-20 9:15 AM EDT
  • Cognetivity Neurosciences Collaborating With Baylor College of Medicine in Ground-Breaking Study on OCD

    Vancouver, British Columbia--(Newsfile Corp. - September 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that its Integrated Cognitive Assessment ("ICA") technology in the form of the FDA-registered CognICATM, will be deployed in a multicenter clinical study (the "Study") conducted by the prestigious Baylor College of Medicine ("Baylor") located...

    2022-09-13 6:00 AM EDT